- Home
- GHI vs REPL Comparison
GHI vs REPL Comparison
Compare GHI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- REPL
- Stock Information
- Founded
- GHI 1998
- REPL 2015
- Country
- GHI United States
- REPL United States
- Employees
- GHI N/A
- REPL N/A
- Industry
- GHI Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- REPL Health Care
- Exchange
- GHI Nasdaq
- REPL Nasdaq
- Market Cap
- GHI 269.5M
- REPL 239.0M
- IPO Year
- GHI N/A
- REPL 2018
- Fundamental
- Price
- GHI $11.02
- REPL $7.60
- Analyst Decision
- GHI Strong Buy
- REPL Buy
- Analyst Count
- GHI 4
- REPL 10
- Target Price
- GHI $16.00
- REPL $8.25
- AVG Volume (30 Days)
- GHI 42.9K
- REPL 22.0M
- Earning Date
- GHI 08-07-2025
- REPL 08-11-2025
- Dividend Yield
- GHI 13.39%
- REPL N/A
- EPS Growth
- GHI N/A
- REPL N/A
- EPS
- GHI 0.45
- REPL N/A
- Revenue
- GHI $34,065,322.00
- REPL N/A
- Revenue This Year
- GHI $228.92
- REPL N/A
- Revenue Next Year
- GHI $4.27
- REPL $194.05
- P/E Ratio
- GHI $24.69
- REPL N/A
- Revenue Growth
- GHI N/A
- REPL N/A
- 52 Week Low
- GHI $10.12
- REPL $2.68
- 52 Week High
- GHI $15.27
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GHI 41.10
- REPL 49.03
- Support Level
- GHI $10.81
- REPL $3.02
- Resistance Level
- GHI $11.45
- REPL $8.07
- Average True Range (ATR)
- GHI 0.25
- REPL 0.93
- MACD
- GHI -0.00
- REPL -0.12
- Stochastic Oscillator
- GHI 28.77
- REPL 46.59
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.